Comparing the Safety and Efficacy of Proton Pump Inhibitors and Histamine-2 Receptor Antagonists in the Management of Patients With Peptic Ulcer Disease: A Systematic Review.

Autor:	Begg M; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Tarhuni M; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfiled, USA., N Fotso M; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Gonzalez NA; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Sanivarapu RR; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfiled, USA., Osman U; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Latha Kumar A; Internal Medicine, Pediatrics, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Sadagopan A; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Mahmoud A; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfiled, USA., Khan S; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2023 Aug 29; Vol. 15 (8), pp. e44341. Date of Electronic Publication: 2023 Aug 29 (Print Publication: 2023).
DOI:	10.7759/cureus.44341
Abstrakt:	Peptic ulcer disease (PUD) refers to the occurrence of an open erosion in the inner lining of the stomach, duodenum, or sometimes lower esophagus. Treatments like proton pump inhibitors (PPIs) or histamine 2 receptor antagonists (H2RAs) are available on the market to efficiently treat the break in the mucosal lining. However, there is little evidence about the effects of the medication on the type and location of the ulcer and the epigastric pain caused by disintegration and increased acidity in the stomach. Given the above, we conducted a systematic review comparing the safety and efficacy of PPIs and H2RAs in various ulcer locations (gastric, duodenal, and pre-pyloric) and the effect of prolonging the treatment with the same medication or changing into a drug from another class in treatment-resistant ulcers. We employed major research literature databases and search engines such as PubMed, Medical Literature Analysis and Retrieval System Online (MEDLINE), Science Direct, and Google Scholar to find relevant articles. After a thorough screening, a quality check using various tools, and applying filters that suited our eligibility criteria, we identified eight articles, of which five were random clinical trials (RCTs), two review articles, and one meta-analysis. This study compares the different side effects of PPIs and H2RAs. Most studies concluded that omeprazole is superior in healing ulcers and bringing pain relief and that patients resistant to H2RAs can be treated better when switched to a PPI. This study also discusses the adverse effects of chronic use, such as diarrhea, constipation, headaches, and gastrointestinal infections. Patients on long-term PPI therapy are required to take calcium supplements to prevent the risk of fractures in older adults. Regarding long-term outcomes, PPIs remain the mainstay of treatment for peptic ulcer disease, based on the papers we reviewed. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2023, Begg et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu